Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of MK-0616 and Atorvastatin
NCT06699355Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enlicitide in hypercholesterolemia (3 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Atorvastatin and its Metabolites up to 8 days, Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Atorvastatin and its Metabolites up to 8 days and 13 more. Started Nov 2023; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06699355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06699355.